

Gibson Dunn Advises BioCryst Pharmaceuticals on \$400 Million Debt Financing for Acquisition of Astria Therapeutics

Firm News | January 23, 2026

Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a \$400 million senior secured term loan facility, to finance, in part, the acquisition of Astria Therapeutics, Inc.

Gibson Dunn regularly advises life sciences companies on complex financing transactions supporting strategic acquisitions.

The Gibson Dunn finance team involved in the transaction was led by Jin Hee Kim and included Paul Rafla, Jaclyn Wang, Aliya Zuberi, and Ruoqi Wei. Karen Spindler and Meghan Hungate advised on certain licensing and intellectual property matters. Michael Dziuban and Carlo Felizardo advised on certain FDA and regulatory matters. Matt Donnelly, Kate Long, and Jason Zhang advised on certain tax matters.

Related People

[Jin Hee Kim](#)

[Paul Rafla](#)

[Jaclyn Wang](#)

[Aliya Zuberi](#)

[Ruoqi Wei](#)

[Karen A. Spindler](#)

[Meghan M. Hungate](#)

[Michael R. Dziuban](#)

[Carlo Felizardo](#)

[Matt Donnelly](#)

[Kate Long](#)

[Jason Zhang](#)

Related Capabilities

[Finance](#)

[Life Sciences](#)

[Intellectual Property](#)

[Technology Transactions](#)

[FDA and Health Care](#)

[Tax](#)